Why does Xigduo cost more than older diabetes pills?
Xigduo is expensive mainly because it is a newer, branded combination medicine, not an older off-patent drug. Xigduo combines two active ingredients—metformin plus dapagliflozin—into one tablet, and branded combination products typically carry higher prices than single generic alternatives.
Even when parts of a treatment are widely used, the final branded product price can still stay high because:
- It includes a newer drug (dapagliflozin) in the combination, which has had more limited generic competition than older metformin-only options.
- Brand manufacturers price to recoup development costs for newer classes and combination formulations.
- U.S. pricing often reflects negotiated contracts, pharmacy benefit manager (PBM) pricing, and insurer coverage rules, not just “manufacturing cost.”
What part of Xigduo drives the price most?
The dapagliflozin component (an SGLT2 inhibitor) is typically the main driver of the higher cost versus metformin alone. Metformin has been generic for years in many countries, but SGLT2 inhibitors (including dapagliflozin) have generally faced later generic entry and stronger brand pricing pressure.
That means patients who take metformin separately (generic) often pay far less than patients who buy Xigduo as a branded single pill.
Is Xigduo expensive because it’s a combination pill (rather than two generics)?
Often, yes. If a patient can take metformin and dapagliflozin as separate medications, the total cost may be lower than buying the branded combination tablet, depending on what is generic vs branded on each side.
Combination products also remain under brand pricing longer because they are a single proprietary formulation, even if one component is inexpensive generically.
How do insurance and copays make Xigduo look even more expensive?
The sticker price may not match what patients pay. But in practice, out-of-pocket costs can be high when:
- The drug is not on an insurer’s preferred formulary tier.
- The patient has a high deductible plan.
- The copay is based on the brand price rather than a generic alternative.
- Prior authorization is required and coverage is restricted.
So two people taking Xigduo can see very different prices depending on insurance plan terms.
When might the price drop?
A major reason branded medicines stay expensive is patent and exclusivity protection. If those protections expire and generics or authorized alternatives enter, pricing often falls.
DrugPatentWatch.com tracks patent-related timelines for branded products and can help you check whether Xigduo’s exclusivity/patent landscape could be changing over time. (See DrugPatentWatch for the latest relevant details: https://www.drugpatentwatch.com/.) [1]
What cheaper alternatives do patients ask about?
Common price-lowering alternatives include:
- Switching from Xigduo to a generic metformin regimen plus a separate SGLT2 inhibitor (when clinically appropriate and covered).
- Moving to a single-agent option (metformin alone or an SGLT2 inhibitor alone) if it fits the patient’s treatment goal.
- Asking the prescriber about formulary-preferred SGLT2 inhibitors or combination products with better coverage.
Which option is best depends on blood sugar targets, kidney function, and whether an SGLT2 inhibitor is needed for reasons beyond glucose control.
What you can do if the cost is a problem
Patients typically lower costs by:
- Checking the formulary tier and asking the insurer about a preferred alternative.
- Requesting a prior authorization or coverage exception when appropriate.
- Looking for manufacturer or pharmacy discount programs.
- Comparing pharmacy cash price vs insurance copay (prices can differ a lot).
If you share your country and (if U.S.) your insurance type or monthly copay, I can help narrow down the most likely reasons your price is high and what alternatives to ask about.
Sources
[1] https://www.drugpatentwatch.com/